<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Braz. J. Microbiol</journal-id><journal-id journal-id-type="publisher-id">bjm</journal-id><journal-title-group><journal-title>Brazilian Journal of Microbiology</journal-title></journal-title-group><issn pub-type="ppub">1517-8382</issn><issn pub-type="epub">1678-4405</issn><publisher><publisher-name>Sociedade Brasileira de Microbiologia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26273281</article-id><article-id pub-id-type="pmc">4507558</article-id><article-id pub-id-type="doi">10.1590/S1517-838246246220130209</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbial Physiology</subject></subj-group></article-categories><title-group><article-title>Oleanolic acid and ursolic acid inhibit peptidoglycan biosynthesis in
<italic>Streptococcus mutans</italic> UA159</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Soon-Nang</given-names></name><xref ref-type="aff" rid="aff01">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Sug-Joon</given-names></name><xref ref-type="aff" rid="aff02">2</xref></contrib><contrib contrib-type="author"><name><surname>Kook</surname><given-names>Joong-Ki</given-names></name><xref ref-type="aff" rid="aff01">1</xref><xref rid="c01" ref-type="corresp"/></contrib></contrib-group><aff id="aff01"><label>1</label>Korean Collection for Oral Microbiology and
Department of Oral Biochemistry, School of Dentistry, Chosun University, Gwangju, &#x0003e;Republic of Korea, Korean Collection for Oral Microbiology and
Department of Oral Biochemistry, School of Dentistry, Chosun University,
Gwangju, Republic of Korea.</aff><aff id="aff02"><label>2</label>Seoul National University, School of Dentistry, Seoul National University, Seoul, &#x0003e;Republic of Korea, Dental Research Institute, School of Dentistry,
Seoul National University, Seoul, Republic of Korea.</aff><author-notes><corresp id="c01">Send correspondence to J.-K. Kook. Korean Collection for Oral
Microbiology and Department of Oral Biochemistry, School of Dentistry, Chosun
University, 309 Pilmun-daero, 501-759 Dong-Gu, Gwangju, Republic of Korea.
E-mail: <email>jkkook@chosun.ac.kr</email>.</corresp><fn id="fn01" fn-type="other"><p>Associate Editor: Luis Henrique Souza Guimar&#x000e3;es</p></fn></author-notes><pub-date pub-type="epub"><day>01</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2015</year></pub-date><volume>46</volume><issue>2</issue><fpage>613</fpage><lpage>617</lpage><history><date date-type="received"><day>23</day><month>2</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Sociedade Brasileira de
Microbiologia</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>All the content of the journal, except where otherwise noted, is
licensed under a Creative Commons License CC BY-NC.</license-p></license></permissions><abstract><p>In this study, we revealed that OA and UA significantly inhibited the expression
of most genes related to peptidoglycan biosynthesis in <italic>S.
mutans</italic> UA159. To the best of our knowledge, this is the first
report to introduce the antimicrobial mechanism of OA and UA against <italic>S.
mutans</italic>.</p></abstract><kwd-group><kwd>ursolic acid</kwd><kwd>oleanolic acid</kwd><kwd>peptidoglycan biosynthesis</kwd><kwd><italic>Streptococcus mutans</italic> UA159</kwd></kwd-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="1"/><ref-count count="13"/><page-count count="5"/></counts></article-meta></front><body><p>Ursolic acid (UA, (3&#x003b2;)-hydroxy-urs-12-en-28-oic acid), oleanolic acid (OA,
3&#x003b2;-3-hydroxyolean-12-en-28-oic acid), and betulinic acid (BA,
3&#x003b2;-3-hydroxy-lup-20(29)-en-28-oic acid) are derivatives of triterpenoid saponins (<xref rid="B11" ref-type="bibr">Liu, 1995</xref>; <xref rid="B04" ref-type="bibr">Fontanay
<italic>et al.</italic>, 2008</xref>). These compounds are naturally found in a
large variety of vegetables, medicinal herbs, and plants that have been investigated for
antibacterial activity (<xref rid="B04" ref-type="bibr">Fontanay <italic>et
al.</italic>, 2008</xref>). The antimicrobial activity of OA and UA is stronger than
that of BA (<xref rid="B04" ref-type="bibr">Fontanay <italic>et al.</italic>,
2008</xref>). OA and UA inhibit growth of Gram-positive bacteria but not
Gram-negative bacteria (<xref rid="B04" ref-type="bibr">Fontanay <italic>et
al.</italic>, 2008</xref>), but their antimicrobial mechanism is unknown.
Previously, we reported that OA and UA have strong antimicrobial activity against
<italic>Streptococcus mutans</italic> (<xref rid="B08" ref-type="bibr">Kim
<italic>et al.</italic>, 2010</xref>; <xref rid="B09" ref-type="bibr">Kim
<italic>et al.</italic>, 2011</xref>) but BA had no antimicrobial activity
against <italic>S. mutans</italic> (data not shown). One of the characteristic
differences between Gram-positive and Gram-negative bacteria is the thickness of the
peptidoglycan layer. Considering this difference, it has been suggested that the
mechanism of OA and UA antimicrobial activity may be related to inhibition of
peptidoglycan biosynthesis (<xref rid="B06" ref-type="bibr">Horiuchi <italic>et
al.</italic>, 2007</xref>). Thus, the objective of this study was to investigate
the effect of BA, OA, and UA on peptidoglycan biosynthesis in <italic>S. mutans</italic>
UA 159 using the quantitative real-time polymerase chain reaction (qPCR) method to
identify the antimicrobial mechanism against <italic>S. mutans</italic>.</p><p>
<italic>S. mutans</italic> UA159 was a kind gift from Dr. Robert A. Burne, Department of
Oral Biology, College of Dentistry, University of Florida. The strain was cultured in
brain heart infusion (BHI) broth (Difco, Lab., Detroit, MI, USA) or on BHI agar plates
in a 37 &#x000b0;C incubator.</p><p>Overnight cultures (1 mL) of <italic>S. mutans</italic> UA 159 were transferred to 9 mL
BHI broth and grown at 37 &#x000b0;C to the mid-log phase (OD<sub>600</sub> = 0.35). UA (Sigma,
St. Louis, MO, USA), OA (Sigma), or BA (Sigma) solutions were added to each tube to a
final concentration of 64 &#x003bc;g/mL. The bacterial culture solutions were incubated in a 37
&#x000b0;C incubator for 90 min and then harvested by centrifugation at 10,000 &#x000d7;
<italic>g</italic> for 10 min at 4 &#x000b0;C. After discarding the supernatant, liquid
nitrogen was immediately added to the tube. The frozen bacterial pellets were
homogenized using a mortar and pestle (Smile Science, Seoul, Korea). Total RNAs were
extracted from the homogenized bacteria following the manufacturer's instructions of the
RNAqueous<sup>&#x000ae;</sup> kit (Ambion, Austin, TX, USA). DNase I treatment was conducted
to completely remove the bacterial genomic DNAs using a TURBO DNA-<italic>free</italic>&#x02122;
Kit (Ambion) according to the manufacturer's protocol. RNA concentration was determined
at 260 nm 280 nm with a UV spectrophotometer (Ultrospec 2000, Pharmacia Biotech.,
UK).</p><p>We consulted the KEGG pathway database to determine the target genes related to
<italic>S. mutans</italic> UA159 peptidoglycan biosynthesis (KEGG pathway). qPCR
primers were designed based on the nucleotide sequences of the target genes (GenBank
accession no. AE014133.2) using the MegAlign and PrimerSelect programs (Lasergene&#x02122; 8.0,
DNAStar, Inc., Madison, WI, USA) (<xref rid="t01" ref-type="table">Table 1</xref>). The
qPCR primers were synthesized by Bioneer Co. (Daejeon, Korea).</p><table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title>Quantitative real-time polymerase chain reaction (qPCR) primers used in this
study.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" align="left" rowspan="1" colspan="1">Genes</th><th valign="bottom" align="left" rowspan="1" colspan="1">Primer names and oligonucleotide sequences
(5 &#x02013; &#x0003e; 3)</th><th valign="bottom" align="center" rowspan="1" colspan="1">Size of amplicon (bp)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>glmU</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-glmU-F:
TGATCCTTTCGGTTATGGTCGTAT<break/>UA159-glmU-R:
CGTTCCCGTGTTAATTTCTTTGA</td><td valign="top" align="center" rowspan="1" colspan="1">118</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murA</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murA-F1:
CCTCCGGGCATAGAAACCTTAG<break/>UA159-murA-R1:
ATTTTAGATGTGGCTCCTTATGAA</td><td valign="top" align="center" rowspan="1" colspan="1">110</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murB</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murB-F1:
CGAGATATGCGCTTTGGTT<break/>UA159-murB-R1: AACGCTGCATTTCCTGACTG</td><td valign="top" align="center" rowspan="1" colspan="1">121</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murC</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murC-F1:
GGTAACCATTTTCGAGAGCATAGG<break/>UA159-murC-R1:
ACACGGATTGGAAAAAGCAGGAA</td><td valign="top" align="center" rowspan="1" colspan="1">140</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murC2</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murC2-F:
CAAATGGATCGTTACGGTGAAAT<break/>UA159-murC2-R:
TTGGCGTTAAAGAGTGGGCTATC</td><td valign="top" align="center" rowspan="1" colspan="1">116</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murD</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murD-F:
TCAAACGCAGGCAAAGATTATTC<break/>UA159-murD-R:
TTTCAACATTATGGCTTCCTGGTA</td><td valign="top" align="center" rowspan="1" colspan="1">143</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murE</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murE-F1:
CGTCCGGCCATGATTTCTACCA<break/>UA159-murE-R1:
GCTCTCGGGGGTTGTTAGTTTTGA</td><td valign="top" align="center" rowspan="1" colspan="1">81</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>alr</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-alr-F:
AGAAGGCGGGAGCGACTG<break/>UA159-alr-R: CAATTGACTGATAAGGGTGGTAAA</td><td valign="top" align="center" rowspan="1" colspan="1">116</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>ddI</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159- D-Ala-F:
AGATGTGGCTTTTTATGATTACGA<break/>UA159- D-Ala-R:
AAAGTCCACAGCAGCCCAAAGT</td><td valign="top" align="center" rowspan="1" colspan="1">146</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murI</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murI-F:
AATGGGCCGTAAAAGTGGATAATG<break/>UA159-murI-R: TGCCCCAAATTTGTTCCTAT</td><td valign="top" align="center" rowspan="1" colspan="1">147</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murF</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murF-F1:
GGTGCTGGCAGATATGAAAGAAT<break/>UA159-murF-R1:
AGTGGTCCAAAAAGAAAAATACGA</td><td valign="top" align="center" rowspan="1" colspan="1">111</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>bacA</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-bacA-F:
AACGGCCTTTTTCATTGGTCTG<break/>UA159-bacA-R: GTTGCGACTTGCCGACTGG</td><td valign="top" align="center" rowspan="1" colspan="1">114</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>mraY</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-mraY-F:
CTTTGCATTTGGGCGTGTTTTA<break/>UA159-mraY-R: GAAGCCAAGCCATCAATACCATC</td><td valign="top" align="center" rowspan="1" colspan="1">100</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murG</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murG-F:
AAGGTGGGTTTGTTTCAGTTCC<break/>UA159-murG-R: GCAATTCGGTTAGCCAGTCC</td><td valign="top" align="center" rowspan="1" colspan="1">106</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murM</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">SM159-murM-F:
TATTTTTGGCAGTACGGATGGAT<break/>SM159-murM-R: ATGGCTGGGACAAACAAGTGA</td><td valign="top" align="center" rowspan="1" colspan="1">131</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>murN</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-murN-F:
AAACAAAGAGACTGCCTGCTAAGA<break/>UA159-murN-R:
AAAACCAATTGCGTGAACTGTC</td><td valign="top" align="center" rowspan="1" colspan="1">123</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>pbp1a</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-pbp1a-F:
TTGATGCCGCTGGATTAGATACTG<break/>UA159-pbp1a-R:
CACTGCTGGCACCATACTTTTGTT</td><td valign="top" align="center" rowspan="1" colspan="1">132</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>pbp1b</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-pbp1b-F:
ATGGTGCTTCTCTTGATGATG<break/>UA159-pbp1b-R: CAAAGGCGTGATTATTCTGAT</td><td valign="top" align="center" rowspan="1" colspan="1">132</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>pbp2a</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-pbp2a-F:
TATGTTGAAGGGTCCGGGTATCTA<break/>UA159-pbp2a-R: CGGTTCCCCATTCCCACTTT</td><td valign="top" align="center" rowspan="1" colspan="1">150</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>pbp2b</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-pbp2b-F1:
ACCGCGTTGGAACATCTTATCT<break/>UA159-pbp2b-R1:
TAGTCCCTTTGGCAGTGGTCTTA</td><td valign="top" align="center" rowspan="1" colspan="1">129</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>pbp2X</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-pbp2X-F:
AAAGACGGACAAGTGACCTACCAA<break/>UA159-pbp2X-R:
CCATCTGCGTTTCCAAATAAGTCT</td><td valign="top" align="center" rowspan="1" colspan="1">145</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>dacA</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1">UA159-dacA-F:
GTACCGCCAACTTTTTCAGC<break/>UA159-dacA-R: CAGCGCCAGCAATGTCC</td><td valign="top" align="center" rowspan="1" colspan="1">120</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">16S rDNA</td><td valign="top" align="left" rowspan="1" colspan="1">SM159-16S -F:
CACACCGCCCGTCACACCAC<break/>SM159-16S -R: CCAGCCGCACCTTCCGATACG</td><td valign="top" align="center" rowspan="1" colspan="1">137</td></tr></tbody></table><table-wrap-foot><fn id="TFN01"><p>
<italic>glmU</italic>, UDP-<italic>N</italic>-acetylglucosamine
pyrophosphorylase gene; <italic>murA</italic>,
UDP-<italic>N</italic>-acetylglucosamine 1-carboxyvinyltransferase gene;
<italic>murB</italic>,
UDP-<italic>N</italic>-acetylenolpyruvoylglucosamine reductase gene;
<italic>murC</italic>, UDP-<italic>N</italic>-acetyl muramate-alanine
ligase gene; <italic>murC2</italic>, UDP-<italic>N</italic>-acetylmuramyl
tripeptide synthetase gene; <italic>murD</italic>,
UDP-<italic>N</italic>-acetylmuramoyl-L-alanyl-D-glutamate synthetase gene;
<italic>murE</italic>,
UDP-<italic>N</italic>-acetylmuramoyl-L-alanyl-D-glutamate-L-lysine ligase
gene; <italic>alr</italic>, alanine racemase gene; <italic>ddI</italic>,
D-alanine-D-alanine ligase gene; <italic>murI</italic>, glutamate racemase
gene; <italic>murF</italic>,
UDP-<italic>N</italic>-acetylmuramoyl-tripeptide&#x02014;D-alanyl-D-alanine ligase
gene; <italic>bacA</italic>, undecaprenyl pyrophosphate phosphatase gene;
<italic>mraY</italic>,
phospho-<italic>N</italic>-acetylmuramoyl-pentapeptide-transferase gene;
<italic>murG</italic>, undecaprenyldiphospho-muramoylpentapeptide
beta-<italic>N</italic>-acetylglucosaminyltransferase gene;
<italic>murM</italic>,
UDP-<italic>N</italic>-acetylmuramoylpentapeptide-lysine
N6-alanyltransferase gene; <italic>murN</italic>, alanine adding enzyme
gene; <italic>pbp1a</italic>, penicillin binding protein 1a gene;
<italic>pbp1b</italic>, penicillin binding protein 1b gene;
<italic>pbp2a</italic>, penicillin binding protein 2a gene;
<italic>pbp2b</italic>, penicillin binding protein 2b gene;
<italic>pbp2X</italic>, penicillin binding protein 2&#x000d7; gene;
<italic>dacA</italic>, serine-type D-Ala-D-Ala carboxypeptidase
(DD-transpeptidase, DacA) gene; 16S rDNA, 16S ribosomal RNA gene.</p></fn></table-wrap-foot></table-wrap><p>First-strand cDNAs synthesis was performed with 4 &#x003bc;g of total RNA, random hexamers, and
an <italic>AccuPower</italic>
<sup>&#x000ae;</sup>
<italic>RocketScript</italic>&#x02122; RT PreMix (Bioneer Co., Deajeon, Korea) using the
<italic>Exicycler</italic>&#x02122; 96 Real-Time Quantitative Thermal Block (Bioneer Co.)
and following the manufacturer's protocol. qPCR was performed with the
AccuPower<sup>&#x000ae;</sup>
<italic>GreenStar</italic>&#x02122; qPCR PreMix (Bioneer Co.) using the
<italic>Exicycler</italic>&#x02122; 96 Real-Time Quantitative Thermal Block. Each PCR
reaction was performed in a total volume of 20 &#x003bc;L containing 1 &#x003bc;L each of the forward
and reverse primers (final concentration, 500 nM each), 0.63 &#x003bc;L cDNA, and the
appropriate dose of sterilized DNase-RNase-free water in PreMix PCR tubes. The qPCR
conditions were initial denaturation at 95 &#x000b0;C for 3 min, 40 cycles of denaturation at 95
&#x000b0;C for 15 sec, primer annealing and extension at 55 &#x000b0;C for 15 sec, and final cooling at
25 &#x000b0;C for 1 min. Each qPCR reaction was performed in triplicate.</p><p>The expression levels of each target gene in the group were normalized with those of 16S
rDNA. The normalized expression of each gene (N) was determined as:</p><disp-formula id="e01"><mml:math id="m1"><mml:mrow><mml:mtext>N</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:msup><mml:mtext>Ct</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>Ct&#x02009;value&#x02009;of&#x02009;the&#x02009;target&#x02009;gene&#x02009;-&#x02009;Ct&#x02009;value&#x02009;of&#x02009;</mml:mtext><mml:mn>16</mml:mn><mml:mtext>S&#x02009;rDNA</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula><p>Relative expression of the target genes between each experimental group (BA, OA, or UA)
and the negative control group (1% DMSO) was calculated as [N of each experimental group
(BA, OA, or UA)/N of the negative control group].</p><p>Data are expressed as mean &#x000b1; standard deviation. Independent sample two-tailed
<italic>t</italic>-tests were conducted to calculate the <italic>p</italic>-values
using SPSS version 12 software (SPSS Inc., USA). A p-value &#x02264; 0.05 was considered
statistically significant.</p><p>We determined the BA, OA, and UA concentration of 64 &#x003bc;g/mL by investigating the
antimicrobial mechanism against <italic>S. mutans</italic> UA159 by calculating the
growth curve at 16, 32, and 64 &#x003bc;g/mL BA, OA, and UA for 60, 90, 120, and 180 min in
<italic>S. mutans</italic> UA159 at the mid-log phase (OD<sub>600</sub> = 0.35). The
growth of <italic>S. mutans</italic> UA159 was in a static (inhibited) state at
concentrations of 64 and 32 &#x003bc;g/mL of OA and UA, but in the exponential state at
concentrations of 64 and 32 &#x003bc;g/mL in the BA-treated and control groups (data not shown).
We decided to further explore using 64 &#x003bc;g/mL BA, OA, and UA.</p><p>The synthesis of UDP-<italic>N</italic>-acetylglucosamine (UDP-GlcNAc) and
UDP-<italic>N</italic>-actetylmuramic acid (UDP-MurNAc), the building blocks of
peptidoglycan, is the first phase of first stage (stage I) of intracellular
peptidoglycan assembly (<xref rid="B02" ref-type="bibr">Bugg and Walsh, 1992</xref>).
UDP-GlcNAc is synthesized from GlcNAc-1-P by UDP-<italic>N</italic>-acetylglucosamine
pyrophosphorylase (GlmU). UDP-MurNAc is synthesized from UDP-GlcNAc by
UDP-<italic>N</italic>-acetylglucosamine 1-carboxyvinyltransferase (MurA) and
UDP-<italic>N</italic>-acetylenolpyruvoylglucosamine reductase (MurB) (<xref rid="B02" ref-type="bibr">Bugg and Walsh, 1992</xref>). The data showed that UA and
OA, but not BA, significantly downregulated <italic>glmU</italic>,
<italic>murA</italic>, and <italic>murB</italic> expression (<xref rid="f01" ref-type="fig">Figure 1A</xref>). Interestingly, <italic>glmU</italic> was
overexpressed by a factor of two in the BA-treated group compared to that in the control
group. The second phase of stage I of peptidoglycan biosynthesis is the assembly of the
UDP-MurNAc-pentapeptide (<xref rid="B02" ref-type="bibr">Bugg and Walsh, 1992</xref>).
The D-amino acids, D-alanine, D-glutamate, and DL-diaminopimelate, occur in
peptidoglycan (<xref rid="B02" ref-type="bibr">Bugg and Walsh, 1992</xref>). For
<italic>S. mutans</italic> UA159, D-alanine and D-glutamate are catalyzed by alanine
racemase (Alr) and glutamate racemase (MurI), respectively (the KEEG pathway).
Biosynthesis of DL-diaminopimelate (DL-DAP) is catalyzed by DAP epimerase or meso-DAP
D-dehydrogenase (<xref rid="B02" ref-type="bibr">Bugg and Walsh, 1992</xref>). These
genes are missing in <italic>S. mutans</italic> UA159, even though
UDP-<italic>N</italic>-acetylmuramyl tripeptide synthetase (MurC2) which catalyzes
adding DL-DAP to UDP-MurNAc-L-alanine-D-glutamate occurs (KEEG Pathway). The reason for
the discrepancy is unclear, but it is possible that DL-DAP is synthesized through an
unknown pathway or that DL-DAP is not used in peptidoglycan synthesis in <italic>S.
mutans</italic> UA159. Generally, DL-DAP is added as the third residue in the
pentapeptide of Gram-negative bacteria and some Gram-positive bacteria, whereas lysine
is added in other Gram-positive bacteria (<ext-link ext-link-type="uri" xlink:href="http://www.enzyme-database.org/reaction/polysacc/PepGly1.html">http://www.enzyme-database.org/reaction/polysacc/PepGly1.html</ext-link>). Using
these D-amino acids and D-Ala-D-Ala formed by D-alanine-D-alanine ligase (DdI), two
types of UDP-MurNAc-pentapeptide, UDP-MurNAc-L-Ala-&#x003b3;-D-Glu-DL-DAP-D-Ala-D-Ala
(UDP-MurNAc-pentapeptide I) and UDP-MurNAc-L-Ala-&#x003b3;-D-Glu-DL-DAP-D-Ala-D-Ala
(UDP-MurNAc-pentapeptide II) are synthesized by UDP-<italic>N</italic>-acetyl
muramate-alanine ligase (MurC),
UDP-<italic>N</italic>-acetylmuramoyl-L-alanyl-D-glutamate synthetase (MurD), MurC2 or
UDP-<italic>N</italic>-acetylmuramoyl-L-alanyl-D-glutamate-L-lysine ligase (MurE),
and UDP-<italic>N</italic>-acetylmuramoyl-tripeptide-D-alanyl-D-alanine ligase (MurF)
(the KEGG Pathway). The data showed that second stage-related genes were downregulated
by OA and UA, but <italic>murE</italic> was downregulated only by BA (<xref rid="f01" ref-type="fig">Figure 1A</xref>). These results reveal that OA and UA inhibited
expression from the first stages of <italic>S. mutans</italic> UA159 peptidoglycan
biosynthesis, whereas BA induced overexpression of UDP-GlcNAc, the first substrate for
peptidoglycan synthesis.</p><fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Relative expression of genes related to peptidoglycan biosynthesis, (A) stage
I and (B) stage II and III, in <italic>Streptococcus mutans</italic> UA159
following treatment with betulinic acid (BA), oleanolic acid (OA), or ursolic
acid (UA). <italic>glmU</italic>, UDP-N-acetylglucosamine pyrophosphorylase;
<italic>murA</italic>, UDP-N-acetylglucosamine 1-carboxyvinyltransferase;
<italic>murB</italic>, UDP-N-acetylenolpyruvoylglucosamine reductase;
<italic>murC</italic>, UDP-N-acetyl muramate-alanine ligase;
<italic>murC2</italic>, UDP-N-acetylmuramyl tripeptide synthetase;
<italic>murD</italic>, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate synthetase;
<italic>murE</italic>, UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-L-lysine
ligase; <italic>alr</italic>, alanine racemase; <italic>ddI</italic>,
D-alanine-D-alanine ligase; <italic>murI</italic>, glutamate racemase;
<italic>murF</italic>, UDP-N-acetylmuramoyl-tripeptide&#x02014;D-alanyl-D-alanine
ligase; <italic>bacA</italic>, undecaprenyl pyrophosphate phosphatase;
<italic>mraY</italic>, phospho-N-acetylmuramoyl-pentapeptide-transferase;
<italic>murG</italic>, undecaprenyldiphospho-muramoylpentapeptide
beta-N-acetylglucosaminyltransferase; <italic>murM</italic>,
UDP-N-acetylmuramoylpentapeptide-lysine N6-alanyltransferase;
<italic>murN</italic>, alanine adding enzyme; <italic>pbp1a</italic>,
penicillin binding protein 1a; <italic>pbp1b</italic>, penicillin binding
protein 1b; <italic>pbp2a</italic>, penicillin binding protein 2a;
<italic>pbp2b</italic>, penicillin binding protein 2b;
<italic>pbp2x</italic>, penicillin binding protein 2x,
<italic>dacA</italic>, serine-type D-Ala-D-Ala carboxypeptidase
(DD-transpeptidase, DacA). <sup>*</sup>p &#x02264; 0.05, significantly downregulated or
upregulated compared with the control group.</title></caption><graphic xlink:href="1517-8382-bjm-46-2-613-gf01"/></fig><p>The second stage (stage II) of peptidoglycan biosynthesis is transport of the
MurNAc-pentapeptide portion of the UDP-MurNAc-pentapeptide across the cytoplasmic
membrane by a undecaprenyl lipid carrier, undecaprenyl phosphate (UP), which is
synthesized from undecaprenyl pyrophosphate (UPP) by undecaprenyl pyrophosphate
phosphatase (BacA) (<xref rid="B05" ref-type="bibr">Higashi <italic>et al.</italic>,
1970</xref>; <xref rid="B01" ref-type="bibr">Bouhss <italic>et al.</italic>,
2008</xref>). The coupling of UDP-MurNAc-pentapeptide to UP to produce
UPP-MurNAc-pentapeptide (Lipid I) and UMP is catalyzed by
phospho-<italic>N</italic>-acetylmuramoyl-pentapeptide-transferase (MraY). Then, another
glucosamine residue, GlcNAc, is attached to Lipid I by
undecaprenyldiphospho-muramoylpentapeptide
beta-<italic>N</italic>-acetylglucosaminyltransferase (MurG) and forms
UPP-MurNAc-(GlcNAc)-pentapeptide (Lipid II). 2 L-Alanine (L-Ala) is added to
UDP-MurNAc-(GlcNAc)-L-Ala-&#x003b3;-D-Glu-L-Lys-D-Ala-D-Ala by
UDP-<italic>N</italic>-acetylmuramoylpentapeptide-lysine N6-alanyltransferase (MurM) and
another alanine-adding enzyme (MurN) to form
UDP-MurNAc-(GlcNAc)-L-Ala-&#x003b3;-D-Glu-L-Lys-(L-Ala)<sub>2</sub>-D-Ala-D-Ala (the KEGG
pathway). The data showed that OA and UA significantly inhibited expression of
<italic>bacA</italic>, <italic>mraY</italic>, <italic>murG</italic>,
<italic>murM</italic>, and <italic>murN</italic> and that BA also downregulated
these genes, except <italic>murM</italic> and <italic>murN</italic> (<xref rid="f01" ref-type="fig">Figure 1B</xref>). These findings reveal that OA, UA, and BA
inhibited translocation of the MurNAc-pentapeptide, an intermediate or monomer of
peptidoglycan in the cell wall.</p><p>The last stage (stage III) of peptidoglycan biosynthesis is transglycosylation,
transpeptidation, and trimming of the peptidoglycan, which are catalyzed by
penicillin-binding proteins (PBPs) and transpeptidase (<xref rid="B13" ref-type="bibr">Pinho <italic>et al.</italic>, 2001</xref>; <xref rid="B10" ref-type="bibr">Lee
<italic>et al.</italic>, 2003</xref>; <xref rid="B12" ref-type="bibr">Mainardi
<italic>et al.</italic>, 2005</xref>; <xref rid="B03" ref-type="bibr">Fan
<italic>et al.</italic>, 2007</xref>). <italic>S. mutans</italic> UA159 has five
PBPs such as PBP1a, PBP1b, PBP2a, PBP2b, and PBP2X, as well as serine-type D-Ala-D-Ala
carboxypeptidase (DacA), which is involved in the last stage of peptidoglycan
biosynthesis (the KEEG pathway). The data showed that these genes, except PBP1a and
PBP1b, were downregulated 52&#x02013;85% and 31&#x02013;56% in the OA and UA groups compared to those in
the control group. Our qPCR data showed that OA and UA significantly downregulated the
PBP genes, except <italic>pbp1a</italic> and <italic>pbp1b</italic>, whereas BA
significantly upregulated these genes, except <italic>pbp1b</italic> and
<italic>pbp2a</italic> (<xref rid="f01" ref-type="fig">Figure 1B</xref>). These
results indicate that OA and UA inhibit polymerization between a newly synthesized
peptidoglycan monomer and the existing peptidoglycan, and that BA increased
polymerization in <italic>S. mutans</italic> UA159.</p><p>In summary, OA and UA inhibited the expression of peptidoglycan biosynthesis-related
genes of <italic>S. mutans</italic> UA159 at the transcriptional level which might be
the one of the antimicrobial mechanism of OA and UA against <italic>S.
mutans</italic>.</p></body><back><ack><title>Acknowledgments</title><p>This study was supported by a grant from the Korea Healthcare Technology R&#x00026;D
Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea
(A091074).</p></ack><ref-list><title>References</title><ref id="B01"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouhss</surname><given-names>A</given-names></name><name><surname>Trunkfield</surname><given-names>AE</given-names></name><name><surname>Bugg</surname><given-names>TD</given-names></name><etal/></person-group><year>2008</year><article-title>The biosynthesis of peptidoglycan lipid-linked
intermediates</article-title><source>FEMS Microbiol Rev</source><volume>32</volume><fpage>208</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">18081839</pub-id></element-citation></ref><ref id="B02"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugg</surname><given-names>TD</given-names></name><name><surname>Walsh</surname><given-names>CT</given-names></name></person-group><year>1992</year><article-title>Intracellular steps of bacterial cell wall peptidoglycan
biosynthesis: enzymology, antibiotics, and antibiotic
resistance</article-title><source>Nat Prod Rep</source><volume>9</volume><fpage>199</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">1436736</pub-id></element-citation></ref><ref id="B03"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><etal/></person-group><year>2007</year><article-title>Diversity of penicillin-binding proteins. Resistance factor FmtA
of <italic>Staphylococcus aureus</italic>
</article-title><source>J Biol Chem</source><volume>282</volume><fpage>35143</fpage><lpage>35152</lpage><pub-id pub-id-type="pmid">17925392</pub-id></element-citation></ref><ref id="B04"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fontanay</surname><given-names>S</given-names></name><name><surname>Grare</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><etal/></person-group><year>2008</year><article-title>Ursolic, oleanolic and betulinic acids: antibacterial spectra and
selectivity indexes</article-title><source>J Ethnopharmacol</source><volume>120</volume><fpage>272</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">18835348</pub-id></element-citation></ref><ref id="B05"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Higashi</surname><given-names>Y</given-names></name><name><surname>Strominger</surname><given-names>JL</given-names></name><name><surname>Sweeley</surname><given-names>CC</given-names></name></person-group><year>1970</year><article-title>Biosynthesis of the peptidoglycan of bacterial cell walls. XXI.
Isolation of free C55-isoprenoid alcohol and of lipid intermediates in
peptidoglycan synthesis from <italic>Staphylococcus
aureus</italic>
</article-title><source>J Biol Chem</source><volume>245</volume><fpage>3697</fpage><lpage>3702</lpage><pub-id pub-id-type="pmid">4248530</pub-id></element-citation></ref><ref id="B06"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horiuchi</surname><given-names>K</given-names></name><name><surname>Shiota</surname><given-names>S</given-names></name><name><surname>Hatano</surname><given-names>T</given-names></name><etal/></person-group><year>2007</year><article-title>Antimicrobial activity of oleanolic acid from Salvia officinalis
and related compounds on vancomycin-resistant enterococci
(VRE)</article-title><source>Biol Pharm Bull</source><volume>30</volume><fpage>1147</fpage><lpage>1149</lpage><pub-id pub-id-type="pmid">17541170</pub-id></element-citation></ref><ref id="B07"><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>KEGG Pathway</collab></person-group><year>2013</year><source>Peptidoglycan biosynthesis - <italic>Streptococcus mutans</italic>
UA159</source><comment>Available at: <ext-link ext-link-type="uri" xlink:href="http://www.genome.jp/kegg-bin/show_pathway?smu00550">http://www.genome.jp/kegg-bin/show_pathway?smu00550</ext-link></comment><date-in-citation>Accessed 5 March 2014</date-in-citation></element-citation></ref><ref id="B08"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Ha</surname><given-names>WH</given-names></name><etal/></person-group><year>2010</year><article-title>Antimicrobial effects of oleanolic acid against
<italic>Streptococcus mutans</italic> and <italic>Streptococcus
sobrinus</italic> isolated from a Korean population</article-title><source>Int J Oral Biol</source><volume>35</volume><fpage>191</fpage><lpage>195</lpage></element-citation></ref><ref id="B09"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Kim</surname><given-names>CS</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><etal/></person-group><year>2011</year><article-title>Antimicrobial effects of ursolic acid against mutans streptococci
isolated from Koreans</article-title><source>Int J Oral Biol</source><volume>36</volume><fpage>7</fpage><lpage>11</lpage></element-citation></ref><ref id="B10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Hesek</surname><given-names>D</given-names></name><name><surname>Suvorov</surname><given-names>M</given-names></name><etal/></person-group><year>2003</year><article-title>A mechanism-based inhibitor targeting the DD-transpeptidase
activity of bacterial penicillin-binding proteins</article-title><source>J Am Chem Soc</source><volume>125</volume><fpage>16322</fpage><lpage>16326</lpage><pub-id pub-id-type="pmid">14692773</pub-id></element-citation></ref><ref id="B11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name></person-group><year>1995</year><article-title>Pharmacology of oleanolic acid and ursolic acid</article-title><source>J Ethnopharmacol</source><volume>49</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">8847885</pub-id></element-citation></ref><ref id="B12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mainardi</surname><given-names>JL</given-names></name><name><surname>Fourgeaud</surname><given-names>M</given-names></name><name><surname>Hugonnet</surname><given-names>JE</given-names></name><etal/></person-group><year>2005</year><article-title>A novel peptidoglycan cross-linking enzyme for a
beta-lactam-resistant transpeptidation pathway</article-title><source>J Biol Chem</source><volume>280</volume><fpage>38146</fpage><lpage>38152</lpage><pub-id pub-id-type="pmid">16144833</pub-id></element-citation></ref><ref id="B13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinho</surname><given-names>MG</given-names></name><name><surname>Filipe</surname><given-names>SR</given-names></name><name><surname>de Lencastre</surname><given-names>H</given-names></name><etal/></person-group><year>2001</year><article-title>Complementation of the essential peptidoglycan transpeptidase
function of penicillin-binding protein 2 (PBP2) by the drug resistance
protein PBP2A in <italic>Staphylococcus aureus</italic>
</article-title><source>J Bacteriol</source><volume>183</volume><fpage>6525</fpage><lpage>6531</lpage><pub-id pub-id-type="pmid">11673420</pub-id></element-citation></ref></ref-list></back></article>